ID: ALA5185420

Max Phase: Preclinical

Molecular Formula: C22H23ClN2O3S

Molecular Weight: 430.96

Associated Items:

Representations

Canonical SMILES:  O=C(O)Cc1cccc(OCCC2CCN(c3nc4ccc(Cl)cc4s3)CC2)c1

Standard InChI:  InChI=1S/C22H23ClN2O3S/c23-17-4-5-19-20(14-17)29-22(24-19)25-9-6-15(7-10-25)8-11-28-18-3-1-2-16(12-18)13-21(26)27/h1-5,12,14-15H,6-11,13H2,(H,26,27)

Standard InChI Key:  XGKJALQUHAMQNR-UHFFFAOYSA-N

Associated Targets(Human)

PPARA Tclin Peroxisome proliferator-activated receptor alpha (9197 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PPARG Tclin Peroxisome proliferator-activated receptor gamma (15191 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PPARD Tchem Peroxisome proliferator-activated receptor delta (6293 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Ppard Peroxisome proliferator-activated receptor delta (358 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 430.96Molecular Weight (Monoisotopic): 430.1118AlogP: 5.26#Rotatable Bonds: 7
Polar Surface Area: 62.66Molecular Species: ACIDHBA: 5HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 4.04CX Basic pKa: 2.47CX LogP: 5.48CX LogD: 2.49
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.55Np Likeness Score: -1.67

References

1. Kato T, Ohara T, Suzuki N, Muto S, Tokuyama R, Mizutani M, Fukasawa H, Matsumura KI, Itai A..  (2022)  Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.,  59  [PMID:35063634] [10.1016/j.bmcl.2022.128567]

Source